Tikcro Technologies (TIKRF) has an investment in BioCancell Therapeutics Inc. (XTAE:BICL) through which the company is engaged in the discovery, development and commercialization of therapies to treat solid cancer tumors. It trades at roughly 50% of net cash and at an EV/EBIT ratio of 5.51x. There is no doubt the company has been something of a value trap over the past decade:
GuruFocus already reported on Steven N. Bronson taking action against the incumbent management in 2007, and he appears to have made some headway as a different CEO has been installed in the meantime. Bronson continues to hold approximately 16% of shares.
News 
Market Data 
Discover 
